NCT06553976 Spastic Paraplegia - Centers of Excellence Research Network
| NCT ID | NCT06553976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Hereditary Spastic Paraplegia |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-06-04 |
| Primary Completion | 2026-06-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-06-04 with a primary completion date of 2026-06-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).
Eligibility Criteria
Inclusion Criteria: * Male or female patients of all ages with a clinical and molecular diagnosis of hereditary spastic paraplegia type 4 (SPG4, SPAST) or hereditary spastic paraplegia type 5A (SPG5A, CYP7B1). Exclusion Criteria: * Not having such a diagnosis and/or not being related to such individual.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06553976 clinical trial?
This trial is open to participants of all sexes, studying Hereditary Spastic Paraplegia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06553976 currently recruiting?
Yes, NCT06553976 is actively recruiting participants. Contact the research team at hsp.research@childrens.harvard.edu for enrollment information.
Where is the NCT06553976 trial being conducted?
This trial is being conducted at Miami, United States, Iowa City, United States, Boston, United States, Boston, United States and 7 additional locations.
Who is sponsoring the NCT06553976 clinical trial?
NCT06553976 is sponsored by Boston Children's Hospital. The trial plans to enroll 100 participants.